Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
462.16
-4.12 (-0.88%)
Feb 13, 2026, 3:48 PM EST
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,849
Profits / Employee
$157,320
Market Cap
375.15B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| OpGen | 1 |
Roche Holding AG News
- 22 hours ago - Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy - Nasdaq
- 22 hours ago - Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease - GlobeNewsWire
- 22 hours ago - Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease - Business Wire
- 6 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Presentation - Seeking Alpha
- 7 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 days ago - Roche Says Experimental Drug Helped Slow Disability In Progressive Multiple Sclerosis Study - Benzinga
- 9 days ago - Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial - GuruFocus
- 9 days ago - Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial - Reuters